Literature DB >> 10811510

Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?

T W Ruhstaller, U Amsler, T Cerny.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10811510     DOI： 10.1023/a:1008371602708

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  20 in total

Review 1.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

2.  High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.

Authors:  A Patrick; A Wee; A Hedderman; D Wilson; J Weiss; M Govani
Journal:  J Neurooncol       Date:  2010-09-26       Impact factor: 4.130

Review 3.  Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review.

Authors:  Takanori Ichikawa; Yasuhiro Shimojima; Dai Kishida; Tomoki Kaneko; Yoshiki Sekijima
Journal:  Rheumatol Int       Date:  2020-04-06       Impact factor: 2.631

Review 4.  Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.

Authors:  Jeffrey M Gelfand; Bruce A C Cree; Stephen L Hauser
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 5.  The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

Authors:  Per Soelberg Sorensen; Morten Blinkenberg
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

6.  Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.

Authors:  H Pels; H Schulz; O Manzke; E Hom; A Thall; A Engert
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

7.  Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

Authors:  Robert Cavaliere; Gina Petroni; Maria B Lopes; David Schiff
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

8.  Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience.

Authors:  K Ina Ly; Laura L Crew; Carrie A Graham; Maciej M Mrugala
Journal:  Oncol Lett       Date:  2016-03-30       Impact factor: 2.967

9.  Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.

Authors:  Jon Glass; Minhee Won; Christopher J Schultz; Daniel Brat; Nancy L Bartlett; John H Suh; Maria Werner-Wasik; Barbara Jean Fisher; Marcia K Liepman; Mark Augspurger; Felix Bokstein; Joseph A Bovi; Matthew C Solhjem; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

10.  Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.

Authors:  Gareth Gregory; Ashwini Arumugaswamy; Teresa Leung; Kah-Lok Chan; Melody Abikhair; Constantine Tam; Ashish Bajel; Lawrence Cher; Andrew Grigg; David Ritchie; Stephen Opat
Journal:  Neuro Oncol       Date:  2013-03-15       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.